GuruFocus Manual of Stocks™  |  Jul 07, 2025
Usana Health Sciences Inc (NYSE:USNA)
www.gurufocus.com/stock/NYSE:USNA/summary
Usana Health Sciences Inc (NYSE:USNA)
[1]
Possible Value Trap, Think Twice[5]$ 32.77
GF Score: 68/100Market Cap: $ 610 Mil
Industry: Consumer Defensive - Consumer Packaged Goods
IPO Date: 1993-04-22
Usana Health Sciences Inc is a direct selling and direct-to-consumer nutrition, personal health and wellness company. It developed and manufactured science-based nutritional, personal care and skincare products with a focus on promoting long-term health and wellness. The company has two reportable segments: direct selling and Hiya direct-to-consumer. The direct selling segment develops a... read more
Latest FY Operating Revenue by Business Segment
Business Segment Name2024Percentage
Direct selling845.7998.98%
Other6.740.79%
Hiya direct-to-consumer1.970.23%
Financial Strength
Rank: 9 /10CurrentIndustry MedianHistorical Median
Cash-to-Debt7.810.52No Debt
Equity-to-Asset0.710.540.71
Interest Coverage89.578.5051387.75
Piotroski F-Score557
Profitability Rank
Rank: 7 /10CurrentIndustry MedianHistorical Median
Operating Margin %6.545.3113.78
Net Margin %3.973.539.65
ROE %6.686.9527.46
ROA %5.083.3318.95
ROC (Joel Greenblatt) %69.0011.55153.85
Growth Rank(* per share data)
Rank: 1 /1010-Yr5-Yr1-Yr
Revenue Growth %4.6-1.9-1.5
EBITDA Growth %2.1-9.4-21.8
Oprt. Income Growth %-0.4-13.6-36.2
EPS w/o NRI Growth %-0.2-12.9-23.1
FCF Growth %-0.3-14.9-17.0
Book Value Growth %10.910.47.4
Momentum Rank
Rank: 4 /10CurrentIndustry MedianHistorical Median
5-Day RSI81.8353.27N/A
9-Day RSI73.7652.03N/A
14-Day RSI68.3251.29N/A
6-1M Momentum %-17.47-1.60N/A
12-1M Momentum %-33.62-2.46N/A
Quarterly
Mar24Jun24Sep24Dec24Mar25
Revenue227.80212.87200.22213.61249.54
Net Income16.5410.4310.614.489.29
EPS0.860.540.560.230.49
Revenue YoY %-8.28-10.64-6.16-3.389.54
Net Income YoY %-10.04-39.67-6.52-73.26-43.82
EPS YoY %-9.47-39.33-5.08-73.56-43.02
Warning Signs
SEVERESloan Ratio: Poor quality of earnings
SEVERERevenue per Share: Declined
SEVEREOperating Margin %: Declined
Good Signs
GOODFinancial Strength: Strong Financial Strength
Insider Trades
InsiderPositionDateTradesCur. Shares
Fleming John TurmanDirector06/09/25-5004,200
Noot WalterCHIEF OPERATING05/27/25-6291--
Iiekking G DougCHIEF FINANCIAL05/09/25-4548--
Fuller Gilbert ADirector05/05/25-674--
Foukas JoshuaCHIEF LEGAL OFF03/12/25-5732--
Neidig BrentCHIEF COMMERCIA03/12/25-4743--
Fleming John TurmanDirector03/11/25-5004,026
Mulham David MulhamCHIEF SALES OFF03/10/25-323412,775
GF Value Rank
Rank: 4 /10CurrentIndustry MedianHistorical Median
PE Ratio18.0118.0816.13
Forward P/E12.5615.49N/A
PB Ratio1.161.454.45
PS Ratio0.710.981.55
P/FCF12.7414.9415.07
Shiller P/E6.7618.0523.54
PEG RatioN/A1.431.40
Valuation Analysis
Current% of Price
NCAV3.4410
Tangible Book12.6939
Graham Number26.5681
Price32.77
GF Value48.12147
EPV70.76216
Median PS Value72.25220
Dividend & Ownership
Dividend Yield (TTM) %N/A
Dividend Yield (Forward) %N/A
Dividend Payout RatioN/A
Dividend Growth (5Y) %N/A
Yield on Cost (5Y) %N/A
Continuous Div. sinceN/A
Insider Ownership %6.44
Institution Ownership %57.93
As of 07-07-2025
* All financial numbers are in millions except for per share data, ratios and percentage change. "Neg. E" means negative equity.
20152016201720182019202020212022202320242025Performance
%GainSP500
1W6.152.20
1M9.785.22
3M28.6616.86
6M-9.406.27
YTD-8.697.34
1Y-27.1314.81
3Y-24.0619.56
5Y-16.8016.53
10Y-7.4213.58
136.25
56.41
23.43
453661
226830.5
2015201620172018201920202021202220232024CurrentKey Data
88.0674.1375.60136.25118.9791.20106.45102.9467.9254.4548.85Highest Stock Price
48.9747.4154.2570.7558.9245.7877.9548.6644.4433.3823.10Lowest Stock Price
1,5951,4981,7792,7751,7011,6221,9631,0221,025684610Market Cap
26.425.024.724.622.821.320.319.319.319.219.1Shares Outstanding-Diluted
17.7915.3429.2722.9917.8113.1617.6614.8216.2416.3918.01PE Ratio
5.684.614.907.094.843.674.972.352.061.291.16PB Ratio
1.831.521.752.441.691.441.741.031.130.800.71PS Ratio
9.528.6710.1611.988.506.568.975.685.715.925.40EV-to-EBITDA
2015201620172018201920202021202220232024TTMPer Share Data
34.8540.1742.3948.2646.4953.3858.3251.7147.6144.5945.86Revenue per Share
3.593.992.535.124.415.865.733.593.302.191.82Earnings per Share
3.334.164.475.714.836.845.334.842.902.662.57Free Cash Flow per Share
----------------------Dividends per Share
9.0211.2012.9314.5314.1018.7017.8920.0323.5312.3912.69Tangible Book per Share
48.1755.5258.5069.8371.4784.2295.2184.4876.6570.8472.25Median PS Value
26.9831.7134.3741.0837.4049.6648.0340.2241.8026.8726.56Graham Number
2015201620172018201920202021202220232024TTMIncome Statement
918.501,0061,0471,1891,0611,1351,186998.60921.01854.50876.24Revenue
758.82825.89867.86988.54873.40925.53968.57804.71744.32693.29705.65Gross Profit
82.6182.0982.8783.1282.3381.5781.6380.5880.8281.1380.53Gross Margin %
617.16687.27735.36800.19727.21749.04798.37697.10651.25626.97648.33Total Operating Expense
141.66138.62132.50188.35146.19176.49170.19107.6193.0766.3257.32Operating Income
15.4213.7812.6515.8413.7815.5514.3410.7810.117.766.54Operating Margin %
94.67100.0462.54126.22100.53124.66116.5169.3563.7942.0634.81Net Income
10.319.945.9710.619.4810.999.826.946.934.923.97Net Margin %
142.60139.00134.69191.55150.56178.46170.70108.81102.7276.6366.62EBIT
152.58152.48150.80208.39173.57200.96192.89130.22123.1198.8694.01EBITDA
37.0533.0118.1733.4727.0631.4327.8516.7213.698.176.68ROE %
24.4722.3812.6323.5118.7721.5319.1211.8110.386.095.08ROA %
2015201620172018201920202021202220232024Mar25Balance Sheet
143.21175.77247.13277.87234.83311.92239.83288.42330.42181.77179.61Cash & Equivalents & MS
244.26277.86340.16392.34329.28425.29365.12384.38417.75279.19281.39Total Current Assets
423.24470.64519.27554.46516.93640.89577.74596.55632.76748.19746.60Total Assets
--------8.328.627.086.898.0629.0123.00Short-Term Debt & CLO
131.41138.49141.18148.69136.10168.07160.79143.83118.85139.63137.38Total Current Liabilities
----------------------Long-Term Debt & CLO
142.39145.36156.06163.32165.22199.24182.62162.08135.56161.86162.72Total Liabilities
280.85325.29363.21391.15351.71441.65395.12434.47497.20532.11529.76Total Stockholders Equity
280.85325.29363.21391.15351.71441.65395.12434.47497.20586.33583.87Total Equity
2015201620172018201920202021202220232024TTMCashflow Statement
111.47136.89123.77152.12126.73160.40121.23103.9070.6460.9958.79Cash Flow from Operations
-25.12-31.88-12.90-69.0047.49-33.96-14.19-12.37-11.98-213.09-212.90Cash Flow from Investing
-49.16-64.86-50.32-105.28-152.05-59.44-181.41-30.09-14.249.557.03Cash Flow from Financing
32.0832.2271.58-33.3020.4578.25-72.2847.6741.93-148.74-148.74Net Change in Cash
143.21178.95250.54217.23237.69315.94243.65291.32333.25184.51182.37Ending Cash Position
-23.73-32.70-13.22-11.43-16.57-15.09-12.76-10.40-14.49-10.07-9.68Capital Expenditure
87.74104.19110.55140.69110.16145.31108.4693.5056.1550.9249.12Free Cash Flow
Competitor(* Up to 5 competitors are listed here. See full competitors list in the Competitive Comparison section below)
TickerCompanyMarket Cap
($M)
PE RatioGF Score
/100
Financial
Strength /10
Profitability
Rank /10
GF Value
Rank /10
Growth
Rank /10
Momentum
Rank /10
NAS:JBSSJohn B Sanfilippo & Son Inc77013.956477431
NAS:SENEASeneca Foods Corp73518.106567351
NYSE:USNAUsana Health Sciences Inc61018.016897414
NAS:WESTWestrock Coffee Co607At Loss3841900
NAS:LWAYLifeway Foods Inc38838.7069107163
GuruFocus Manual of Stocks™  |  Jul 07, 2025
Usana Health Sciences Inc (NYSE:USNA)
www.gurufocus.com/stock/NYSE:USNA/summary

Financial Strength[2] (Quarterly data, as of Mar. 2025) : Good (9/10)

0
1
2
3
4
5
6
7
8
9

Cash-to-Debt : 7.81

Cash-to-Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. A high ratio indicates that a company is better able to pay back its debt, and is thus able to take on more debt if necessary.


Equity-to-Asset : 0.71

Equity-to-Asset ratio is calculated as total stockholders equity divided by its total assets. Equity-to-Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity-to-Asset ratio (more leveraged) may have higher ROE % because of the leverage.


Debt-to-Equity : 0.04

A high Debt-to-Equity ratio generally means that a company has been aggressive in financing its growth with debt.


Piotroski F-Score : 5

The Piotroski F-Score is used to determine the strength of a firm's financial position, with 9 being the best and 0 being the worst.

0
1
2
3
4
5
6
7
8
9


WACC : 10.05% vs ROIC : 7.17%

The weighted average cost of capital (WACC) is the rate that a company is expected to pay on average to all its security holders to finance its assets. Return on invested capital (ROIC) measures how well a company generates cash flow relative to the capital it has invested in its business.


Dividend Yield : 0.00%

Dividend yield is a way to measure how much cash flow you are getting for each dollar invested in an equity position.

GuruFocus Manual of Stocks™  |  Jul 07, 2025
Usana Health Sciences Inc (NYSE:USNA)
www.gurufocus.com/stock/NYSE:USNA/summary

Profitability[3] (Annual data, as of Dec. 2024) : Good (7/10)

0
1
2
3
4
5
6
7
8
9

Revenue : $250 Mil vs Net Income : $9 Mil

Revenue is the amount of money that a company actually receives during a specific period, including discounts and deductions for returned merchandise. Net Income is a company's total profit. Net income is calculated by taking revenues and adjusting for the cost of doing business, depreciation, interest, taxes and other expenses.


Cash & Equivalents : $180 Mil vs Long-Term Debt* : $0 Mil

Cash & equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash. Long-Term Debt* consists of loans and obligations lasting over one year.


Operating Margin % : 6.28%

Operating margin % measures how much profit a company makes on a dollar of sales. Operating Margin % is calculated as Operating Income divided by Revenue.


EPS without NRI : $0.73

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock. In calculating earnings per share without non-recurring items, the dividends of preferred stocks and Non Operating Income need to subtracted from the total net income first.


Dividends per Share : $0.00

Dividends per Share is the amount of dividends that the shareholders of a company receive on a per-share basis. It is calculated using the total dividends paid out to shareholders over one fiscal year and the number of shares outstanding.


Free Cash Flow per Share : $0.66

Free Cash flow per Share is the amount of Free cash flow per outstanding share of the company's stock.

GuruFocus Manual of Stocks™  |  Jul 07, 2025
Usana Health Sciences Inc (NYSE:USNA)
www.gurufocus.com/stock/NYSE:USNA/summary

Valuation (Quarterly data, as of Mar. 2025)

These valuation metrics should give you a sense of reasonable prices, but be careful with them. Always seek to understand why a valuation is changing over time.


Valuation Chart (Current stock price : $32.77)


PE Ratio without NRI : 10.92

The price-to-earnings ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than regular PE Ratio.


PB Ratio : 0.96

The price-to-book ratio measures the valuation of the stock relative to the underlying asset of the company.


PS Ratio : 0.59

The price-to-sales ratio is a valuation ratio that compares a company’s stock price to its revenues. The price-to-sales ratio is an indicator of the value placed on each dollar of a company’s sales or revenues.


Price-to-Free-Cash-Flow : 10.49

Price-to-free-cash-flow is very similar to the valuation metric of price-to-operating-cash-flow but is considered a more exact measure, owing to the fact that it uses free cash flow, which subtracts capital expenditures from a company's total operating cash flow, thereby reflecting the actual cash flow available to fund non-asset-related growth.


EV-to-EBIT : 6.07

Enterprise value of a company divided by its trailing 12 months earnings before interest and taxes (EBIT).

GuruFocus Manual of Stocks™  |  Jul 07, 2025
Usana Health Sciences Inc (NYSE:USNA)
www.gurufocus.com/stock/NYSE:USNA/summary

Valuation Bands

In these charts the 10-year valuation bands of the price-to-earnings ratio (PE Ratio), price-to-book ratio (PB Ratio), price-to-sales ratio (PS Ratio) and price-to-operating-cash-flow ratio (POCF) are drawn together with the historical stock prices. For example, the upper line of the PE band is where the stock price would have been if it were always traded at the maximum PE ratio of the past 10 years. The lower line of the PE band is where the stock price would have been if it were always traded at the lowest PE ratio of the past 10 years. It is always better if the stock price is close to the lower line, which indicates a lower valuation.


Historical Price and PE Band


Historical Price and PS Band


Historical Price and PB Band


Historical Price and Price-to-Operating-Cash-Flow (POCF) Band

GuruFocus Manual of Stocks™  |  Jul 07, 2025
Usana Health Sciences Inc (NYSE:USNA)
www.gurufocus.com/stock/NYSE:USNA/summary

Warning Signs

GuruFocus conducted a thorough checkup using a checklist of 32 items that cover the areas of financial strength, profitability, growth, and valuation of each company. The purpose of Warning Signs is to warn you that the company may have red flags in certain areas, helping to avoid overlooking them. These warning signs do not necessarily mean you should not invest in the stock. But you should be aware of them before you invest.


Severe Warning Signs

Sloan Ratio : Poor quality of earnings

When sloan ratio (25.95)% higher than 25% or lower than -25%, earnings are more likely to be made up of accruals.

Revenue per Share : Declined

Usana Health Sciences Inc revenue per share has been in decline for the last 5 years.

Operating Margin % : Declined

Usana Health Sciences Inc operating margin has been in a 5-year decline. The average rate of decline per year is -11.9%.

Good Signs

Financial Strength : Strong Financial Strength

Usana Health Sciences Inc shows strong financial strength.

Altman Z-Score : Strong

Altman Z-score of 4.85 is strong.

Beneish M-Score : Unlikely manipulator

Beneish M-Score -1.97 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

Interest Coverage : Comfortable

Ben Graham prefers companies' interest coverage to be at least 5. Usana Health Sciences Inc has enough cash to cover all of its debt. Its financial situation is stable.

Medium Warning Signs

PE Ratio : Close to 1-year high

Usana Health Sciences Inc stock PE Ratio (=18.01) is close to 1-year high of 18.01.

ROIC vs WACC : ROIC < WACC

Company's return on invested capital is less than the weighted average cost of capital. It might not be capital efficient

Insider Sell : Insider Selling

There were 4 insider selling transactions and no insider buying over the past 3 months. 12,013 shares were sold.
GuruFocus Manual of Stocks™  |  Jul 07, 2025
Usana Health Sciences Inc (NYSE:USNA)
www.gurufocus.com/stock/NYSE:USNA/summary

Competitive Comparison


5 Year Price Change Comparison



Financial Strength

CompanyFinancial StrengthCash-to-DebtEquity-to-AssetDebt-to-EquityInterest CoveragePiotroski F-ScoreAltman Z-ScoreBeneish M-ScoreWACC %ROIC %
SHSE:603288Foshan Haitian Flavouring and Food Co Ltd10/10157.900.830.01292.88823.89-2.5114.1757.47
NAS:LWAYLifeway Foods Inc10/10178.400.790.00174.44516.07-2.694.4713.72
NAS:NATRNatures Sunshine Products Inc9/105.830.640.091030.6264.92-2.539.7510.00
NYSE:USNAUsana Health Sciences Inc9/107.810.710.0489.5754.85-1.9710.057.17
NAS:MAMAMama's Creations Inc8/100.940.500.4812.60410.69-2.767.9614.84
NAS:JBSSJohn B Sanfilippo & Son Inc7/100.010.590.3527.4225.05-2.245.1313.34
NSE:NESTLEINDNestle India Ltd7/100.180.330.2931.38620.12-2.1212.9432.79
XPAR:BNDanone SA6/100.430.390.805.7882.36-2.644.566.00
NYSE:JBSJBS NV6/100.220.182.872.9953.29-2.196.8613.65
NAS:SENEASeneca Foods Corp6/100.110.540.592.2753.82-3.104.544.99
NYSE:GISGeneral Mills Inc5/100.020.281.666.2752.48-2.604.058.65
NYSE:KKellanova5/100.050.251.596.5673.48-2.576.2311.57
NAS:KHCThe Kraft Heinz Co5/100.130.550.445.7360.88-2.375.3519.83
TSE:2802Ajinomoto Co Inc4/100.400.430.617.4654.39-2.984.896.05
NYSE:BGSB&G Foods Inc4/100.030.174.011.2341.05-2.536.294.96
OTCPK:RAJAFCordyceps Sunshine Biotech Holdings Co Ltd4/100.07-0.08-1.46N/AN/A112.930.0010.342.30
NYSE:HLFHerbalife Ltd4/100.14-0.27-3.261.8952.15-2.309.3126.86
XSWX:NESNNestle SA4/100.120.261.778.4872.81-2.684.419.94
NAS:WESTWestrock Coffee Co4/100.060.301.560.0010.57-2.859.27-3.76
NAS:BYNDBeyond Meat Inc1/100.08-1.01-1.880.004-2.65-4.624.94-32.56
GuruFocus Manual of Stocks™  |  Jul 07, 2025
Usana Health Sciences Inc (NYSE:USNA)
www.gurufocus.com/stock/NYSE:USNA/summary

Competitive Comparison - Cont.


Profitability

CompanyProfitability RankOperating
Margin %
Net Margin %ROE %ROA %Price-to-Free-Cash-FlowROC (Joel Greenblatt) %3-Year Revenue Growth %3-Year EBITDA Growth %3-Year EPS w/o NRI Growth %
SHSE:603288Foshan Haitian Flavouring and Food Co Ltd9/1026.1824.0821.8617.5239.81122.322.40-0.50-2.00
NSE:NESTLEINDNestle India Ltd9/1021.2615.9881.0627.66248.6868.8314.7014.3014.10
XPAR:BNDanone SA8/1012.667.3811.964.4915.3155.974.2010.103.10
NYSE:GISGeneral Mills Inc8/1016.8711.7824.777.0712.9489.264.101.202.20
NYSE:HLFHerbalife Ltd8/108.825.66Neg. E10.536.1866.75-2.80-12.90-25.80
XSWX:NESNNestle SA8/1017.0211.8731.248.1319.2246.934.009.70-13.20
NYSE:JBSJBS NV7/106.282.4426.225.180.0032.2810.90-0.80-15.60
NAS:JBSSJohn B Sanfilippo & Son Inc7/106.995.0017.0310.410.0019.277.102.70-1.10
NYSE:KKellanova7/1015.1210.9338.778.9132.1851.412.502.90-1.50
NAS:LWAYLifeway Foods Inc7/106.305.3914.5211.4481.8642.1617.8028.3041.00
NAS:MAMAMama's Creations Inc7/104.413.4118.799.24113.8045.5233.4074.800.00
NAS:SENEASeneca Foods Corp7/104.932.616.833.102.498.1312.7018.004.00
NYSE:USNAUsana Health Sciences Inc7/106.543.976.685.0812.7469.00-8.60-18.40-23.30
TSE:2802Ajinomoto Co Inc6/107.034.598.943.9740.3915.53-10.50-17.00-20.60
NYSE:BGSB&G Foods Inc6/1010.31-11.16-31.47-6.543.02-13.99-7.900.00-28.10
NAS:NATRNatures Sunshine Products Inc6/104.742.226.514.1417.0428.102.90-6.90-30.70
NAS:KHCThe Kraft Heinz Co6/1020.6310.445.412.9710.7024.700.00-16.301.50
NAS:BYNDBeyond Meat Inc2/10-49.71-49.700.00-22.940.00-32.74-12.406.107.00
OTCPK:RAJAFCordyceps Sunshine Biotech Holdings Co Ltd1/1037.98285.13Neg. E22.590.003.500.000.000.00
NAS:WESTWestrock Coffee Co1/10-4.07-9.62-23.01-7.830.00-7.54-22.200.00-25.10

Valuation

CompanyPE RatioPB RatioPS RatioPrice-to-Intrinsic-Value-Projected-FCFPrice-to-Intrinsic-Value-DCF (Earnings Based)Price-to-Median-PS-ValuePrice-to-Peter-Lynch-Fair-ValuePrice-to-Graham-NumberEarnings Yield (Joel Greenblatt) %Forward Rate of Return (Yacktman) %
NYSE:BGSB&G Foods IncAt Loss0.700.190.250.000.200.000.00-5.1611.30
NAS:BYNDBeyond Meat IncAt Loss0.000.760.000.000.000.000.00-11.110.00
NAS:WESTWestrock Coffee CoAt Loss8.490.670.000.000.000.000.00-3.320.00
NYSE:HLFHerbalife Ltd3.640.000.210.570.000.190.000.0014.1619.62
NAS:KHCThe Kraft Heinz Co12.170.641.270.460.000.710.000.003.4810.96
NYSE:GISGeneral Mills Inc12.963.131.520.881.090.740.000.007.7312.11
NAS:JBSSJohn B Sanfilippo & Son Inc13.952.220.701.020.880.720.001.208.548.25
NYSE:JBSJBS NV14.744.180.361.350.000.951.3913.3810.3311.25
NYSE:USNAUsana Health Sciences Inc18.011.160.710.480.000.450.001.2313.121.30
NAS:SENEASeneca Foods Corp18.101.160.471.110.001.740.000.968.313.05
XSWX:NESNNestle SA18.925.682.251.701.100.780.000.005.795.72
NYSE:KKellanova20.207.092.202.160.001.320.000.005.84-1.25
XPAR:BNDanone SA22.072.501.631.210.001.000.000.006.855.30
NAS:NATRNatures Sunshine Products Inc29.421.790.650.990.001.060.001.519.506.30
SHSE:603288Foshan Haitian Flavouring and Food Co Ltd32.456.817.812.851.790.710.003.204.032.05
NAS:LWAYLifeway Foods Inc38.705.232.063.260.002.261.553.444.2021.22
NSE:NESTLEINDNestle India Ltd71.9257.5311.498.054.831.0012.4913.831.925.99
NAS:MAMAMama's Creations Inc81.7312.792.764.240.001.980.009.171.754.20
TSE:2802Ajinomoto Co Inc113.375.212.995.470.002.327.866.042.9116.23
OTCPK:RAJAFCordyceps Sunshine Biotech Holdings Co Ltd1070.000.002853.330.000.000.000.000.000.010.00
GuruFocus Manual of Stocks™  |  Jul 07, 2025
Usana Health Sciences Inc (NYSE:USNA)
www.gurufocus.com/stock/NYSE:USNA/summary

Peter Lynch Chart[4]

GuruFocus Manual of Stocks™  |  Jul 07, 2025
Usana Health Sciences Inc (NYSE:USNA)
www.gurufocus.com/stock/NYSE:USNA/summary

Per Share Data


Per Share Data

Dec09
Dec10
Dec11
Dec12
Dec13
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Dec22
Dec23
Dec24
TTM Fiscal Period
14.16
16.24
18.68
21.74
25.28
28.87
34.85
40.17
42.39
48.26
46.49
53.38
58.32
51.71
47.61
44.59
45.86
Revenue per Share
1.90
2.41
2.76
3.59
4.42
4.55
5.79
6.09
6.10
8.46
7.61
9.45
9.48
6.74
6.36
5.16
4.92
EBITDA per Share
1.67
2.16
2.49
3.30
4.10
4.23
5.41
5.55
5.45
7.77
6.60
8.40
8.39
5.64
5.31
4.00
3.49
EBIT per Share
1.09
1.43
1.63
2.23
2.78
2.80
3.59
3.99
2.53
5.12
4.41
5.86
5.73
3.59
3.30
2.19
1.82
Earnings per Share (Diluted)
1.07
1.43
1.63
2.23
2.78
2.80
3.59
3.99
4.06
5.16
4.41
5.86
5.73
3.59
3.30
2.59
2.47
EPS without NRI
0.38
1.43
1.60
2.72
3.24
3.97
3.84
4.16
3.65
4.84
4.30
6.11
4.59
3.75
2.12
1.74
1.72
Owner Earnings per Share (TTM)
0.92
1.94
1.91
2.83
3.20
3.10
3.33
4.16
4.47
5.71
4.83
6.84
5.33
4.84
2.90
2.66
2.57
Free Cash Flow per Share
1.05
2.07
2.25
3.11
3.48
3.84
4.23
5.47
5.01
6.17
5.55
7.55
5.96
5.38
3.65
3.18
3.08
Operating Cash Flow per Share
0.45
0.79
1.69
2.56
5.26
4.40
5.73
7.18
10.29
11.79
10.84
14.83
12.37
15.02
17.27
9.54
9.56
Cash per Share
2.43
4.74
5.82
6.71
9.38
9.11
11.25
13.29
15.12
16.60
16.24
20.99
20.38
22.62
25.99
27.91
28.20
Book Value per Share
2.24
2.86
3.80
4.54
7.20
6.78
9.02
11.20
12.93
14.53
14.10
18.70
17.89
20.03
23.53
12.39
12.69
Tangible Book per Share
0.23
--
--
--
--
--
--
--
--
--
0.38
0.41
0.37
0.36
0.42
1.52
1.22
Total Debt per Share
15.95
21.73
15.19
16.47
37.79
51.30
63.88
61.20
74.05
118
78.55
77.10
101
53.20
53.60
35.89
32.77
Month End Stock Price
30.86
31.88
31.15
29.85
28.41
27.38
26.36
25.05
24.71
24.64
22.82
21.26
20.34
19.31
19.35
19.16
19.09
Shares Outstanding (Diluted Average)

Ratios

Dec09
Dec10
Dec11
Dec12
Dec13
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Dec22
Dec23
Dec24
TTM Fiscal Period
63.19
41.59
31.81
36.96
35.43
31.24
37.05
33.01
18.17
33.47
27.06
31.43
27.85
16.72
13.69
8.17
6.68
ROE %
9.62
9.08
12.19
15.09
8.79
5.55
6.52
7.16
3.71
4.72
5.59
8.56
5.60
7.11
6.65
6.33
5.76
ROE % Adjusted to Book Value
27.28
27.90
22.64
25.96
24.86
21.32
24.47
22.38
12.63
23.51
18.77
21.53
19.12
11.81
10.38
6.09
5.08
ROA %
70.77
58.41
50.46
55.56
48.55
41.29
47.76
40.07
21.38
38.65
31.04
35.68
31.47
18.96
15.28
12.26
9.25
Return-on-Tangible-Equity
28.60
34.58
30.72
33.94
30.67
25.56
28.72
25.42
14.11
25.96
20.59
23.45
20.76
12.89
11.27
8.10
6.44
Return-on-Tangible-Asset
90.50
120
131
161
193
178
179
147
132
197
161
182
169
109
104
78.85
69.00
ROC (Joel Greenblatt) %
68.33
60.19
46.82
51.64
49.70
45.01
53.44
44.55
37.93
48.87
38.28
41.81
38.37
25.02
21.25
13.65
11.82
ROCE %
1.75
5.56
4.94
17.89
18.57
12.77
14.99
11.42
-1.71
12.74
4.26
8.54
13.52
-6.16
-4.90
-17.77
-21.40
5-Year RORE %
-96.65
19.51
19.47
144
58.98
-7.11
52.19
24.21
217
-1,326
-181
51.31
404
324
39.18
-7.92
-9.22
1-Year ROIIC %
35.21
36.50
30.14
35.40
38.87
33.49
35.98
34.49
20.96
43.95
33.98
38.65
33.75
20.45
18.39
8.37
7.17
ROIC %
8.26
8.25
9.39
7.06
10.66
15.38
8.27
8.76
2.52
6.53
4.76
6.68
7.91
8.45
7.26
8.63
10.05
WACC %
2.90
1.34
--
--
--
--
--
--
--
--
0.79
5.99
0.73
2.75
3.50
1.52
3.60
Effective Interest Rate on Debt %
79.45
81.55
82.53
82.15
82.26
82.19
82.61
82.09
82.87
83.12
82.33
81.57
81.63
80.58
80.82
81.13
80.53
Gross Margin %
11.62
13.18
13.28
15.13
16.25
14.69
15.42
13.78
12.65
15.84
13.78
15.55
14.34
10.78
10.11
7.76
6.54
Operating Margin %
7.68
8.82
8.72
10.24
11.00
9.69
10.31
9.94
5.97
10.61
9.48
10.99
9.82
6.94
6.93
4.92
3.97
Net Margin %
13.42
14.85
14.77
16.54
17.49
15.76
16.61
15.16
14.40
17.52
16.36
17.71
16.26
13.04
13.37
11.57
10.73
EBITDA Margin %
6.49
11.96
10.22
13.01
12.65
10.72
9.55
10.36
10.56
11.83
10.38
12.81
9.14
9.36
6.10
5.96
5.61
FCF Margin %
0.09
--
--
--
--
--
--
--
--
--
0.02
0.02
0.02
0.02
0.02
0.06
0.04
Debt-to-Equity
0.60
0.71
0.71
0.69
0.71
0.66
0.66
0.69
0.70
0.71
0.68
0.69
0.68
0.73
0.79
0.71
0.71
Equity-to-Asset
0.06
--
--
--
--
--
--
--
--
--
0.02
0.01
0.01
0.01
0.01
0.04
0.03
Debt-to-Asset
0.40
0.29
0.29
0.31
0.29
0.34
0.34
0.31
0.30
0.30
0.32
0.31
0.32
0.27
0.21
0.22
0.22
Liabilities-to-Assets
282
258
214
208
186
181
196
185
175
184
163
160
159
137
121
100
103
Gross-Profit-to-Asset %
1.82
0.93
1.16
1.36
1.35
-1.57
1.18
-4.47
11.91
2.44
0.63
1.76
0.59
1.02
1.44
1.32
1.26
Degree of Financial Leverage
3.55
3.16
2.60
2.54
2.26
2.20
2.37
2.25
2.12
2.22
1.98
1.96
1.95
1.70
1.50
1.24
1.28
Asset Turnover
2.49
2.30
2.34
--
--
--
--
--
--
--
--
--
--
--
--
--
-- Days Sales Outstanding
25.79
23.42
25.84
23.63
23.69
22.40
20.37
19.33
21.19
19.76
21.87
26.81
26.55
23.11
21.81
24.97
20.50
Days Payable
101
114
128
116
120
120
127
133
130
132
147
139
158
156
133
149
141
Days Inventory
77.58
93.25
104
92.12
96.21
97.49
107
113
109
112
125
112
131
133
111
124
121
Cash Conversion Cycle
147
159
156
--
--
--
--
--
--
--
--
--
--
--
--
--
-- Receivables Turnover
3.62
3.19
2.86
3.15
3.04
3.04
2.87
2.75
2.81
2.77
2.49
2.63
2.31
2.34
2.75
2.46
2.58
Inventory Turnover
0.21
0.18
0.17
0.18
0.18
0.18
0.17
0.18
0.17
0.17
0.18
0.18
0.18
0.19
0.19
0.19
0.19
COGS-to-Revenue
0.06
0.06
0.06
0.06
0.06
0.06
0.06
0.07
0.06
0.06
0.07
0.07
0.08
0.08
0.07
0.08
0.08
Inventory-to-Revenue
0.01
0.01
0.02
0.01
0.01
0.03
0.03
0.03
0.01
0.01
0.02
0.01
0.01
0.01
0.02
0.01
0.01
Capex-to-Revenue
0.08
0.06
0.14
0.09
0.07
0.18
0.17
0.24
0.10
0.06
0.11
0.09
0.08
0.10
0.16
0.15
0.17
Capex-to-Operating-Income
0.13
0.06
0.15
0.09
0.08
0.19
0.21
0.24
0.11
0.08
0.13
0.09
0.11
0.10
0.21
0.17
0.17
Capex-to-Operating-Cash-Flow
* All financial numbers are in millions except for per share data, ratios and percentage change. When Return-on-Tangible-Equity displays Neg. E, it means the the tangible equity is negative. When ROE % or ROE % Adjusted to Book Value displays Neg. E, it means the the total shareholders equity is negative.
GuruFocus Manual of Stocks™  |  Jul 07, 2025
Usana Health Sciences Inc (NYSE:USNA)
www.gurufocus.com/stock/NYSE:USNA/summary

Financial Statement

Income Statement

Dec09
Dec10
Dec11
Dec12
Dec13
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Dec22
Dec23
Dec24
TTM Fiscal Period
437
518
582
649
718
790
918
1,006
1,047
1,189
1,061
1,135
1,186
999
921
855
876
Revenue
89.80
95.48
102
116
127
141
160
180
179
201
188
209
218
194
177
161
171
Cost of Goods Sold
347
422
480
533
591
650
759
826
868
989
873
926
969
805
744
693
706
Gross Profit
79.45
81.55
82.53
82.15
82.26
82.19
82.61
82.09
82.87
83.12
82.33
81.57
81.63
80.58
80.82
81.13
80.53
Gross Margin %
296
121
137
154
166
185
209
234
265
275
268
261
279
262
257
263
290
Selling, General, & Admin. Expense
--
233
266
281
308
349
408
453
470
525
459
488
519
435
394
364
358
Other Operating Expense
296
354
403
435
474
534
617
687
735
800
727
749
798
697
651
627
648
Total Operating Expense
50.79
68.22
77.26
98.18
117
116
142
139
133
188
146
176
170
108
93.07
66.32
57.32
Operating Income
11.62
13.18
13.28
15.13
16.25
14.69
15.42
13.78
12.65
15.84
13.78
15.55
14.34
10.78
10.11
7.76
6.54
Operating Margin %
0.08
0.17
0.19
0.25
0.46
0.50
1.12
1.48
2.19
4.43
4.71
2.54
2.52
3.79
9.64
11.32
9.37
  Interest Income
-0.61
-0.09
-0.01
-0.02
-0.00
-0.13
-0.02
-0.44
-0.05
-0.04
-0.07
-0.51
-0.06
-0.19
-0.26
-0.28
-0.64
  Interest Expense
-0.53
0.07
0.18
0.23
0.46
0.37
1.10
1.04
2.14
4.39
4.64
2.03
2.46
3.60
9.38
11.04
8.73
Net Interest Income
0.71
0.58
0.04
0.02
-0.59
-0.82
-0.17
-1.11
-0.00
-1.23
-0.33
-0.57
-2.01
-2.59
0.01
-1.01
-0.07
Other Income (Expense)
50.98
68.86
77.48
98.43
117
116
143
139
135
192
150
178
171
109
102
76.35
65.98
Pre-Tax Income
-17.42
-23.21
-26.73
-31.99
-37.56
-39.02
-47.92
-38.51
-72.11
-65.29
-49.97
-53.28
-54.14
-39.27
-38.67
-34.29
-31.17
Tax Provision
34.18
33.71
34.49
32.50
32.22
33.74
33.60
27.80
53.55
34.09
33.20
29.94
31.73
36.15
37.74
44.91
47.24
Tax Rate %
--
--
0.00
--
--
--
--
--
0.00
0.00
-0.00
-0.00
--
--
-0.00
--
-0.00
Other Net Income (Loss)
33.56
45.65
50.75
66.43
79.02
76.64
94.67
100
62.54
126
101
125
117
69.35
63.79
42.06
34.81
Net Income Including Noncontrolling Interests
33.56
45.65
50.75
66.43
79.02
76.64
94.67
100
62.54
126
101
125
117
69.35
63.79
42.06
34.81
  Net Income (Continuing Operations)
33.56
45.65
50.75
66.43
79.02
76.64
94.67
100
62.54
126
101
125
117
69.35
63.79
42.06
34.81
Net Income
7.68
8.82
8.72
10.24
11.00
9.69
10.31
9.94
5.97
10.61
9.48
10.99
9.82
6.94
6.93
4.92
3.97
Net Margin %
1.10
1.47
1.65
2.29
2.89
2.90
3.72
4.14
2.57
5.24
4.44
5.89
5.78
3.60
3.31
2.20
1.84
EPS (Basic)
1.09
1.43
1.63
2.23
2.78
2.80
3.59
3.99
2.53
5.12
4.41
5.86
5.73
3.59
3.30
2.19
1.82
EPS (Diluted)
30.86
31.88
31.15
29.85
28.41
27.38
26.36
25.05
24.71
24.64
22.82
21.26
20.34
19.31
19.35
19.16
19.09
Shares Outstanding (Diluted Average)
51.59
68.96
77.49
98.45
117
116
143
139
135
192
151
178
171
109
103
76.63
66.62
EBIT
7.07
7.92
8.47
8.83
9.04
8.81
9.98
13.48
16.11
16.84
23.01
22.51
22.19
21.41
20.40
22.23
27.39
Depreciation, Depletion and Amortization
58.66
76.87
85.96
107
126
125
153
152
151
208
174
201
193
130
123
98.86
94.01
EBITDA
13.42
14.85
14.77
16.54
17.49
15.76
16.61
15.16
14.40
17.52
16.36
17.71
16.26
13.04
13.37
11.57
10.73
EBITDA Margin %
* All financial numbers are in millions except for per share data, ratios and percentage change.
GuruFocus Manual of Stocks™  |  Jul 07, 2025
Usana Health Sciences Inc (NYSE:USNA)
www.gurufocus.com/stock/NYSE:USNA/summary

Financial Statement

Cashflow Statement

Dec09
Dec10
Dec11
Dec12
Dec13
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Dec22
Dec23
Dec24
TTM Fiscal Period
33.56
45.65
50.75
66.43
79.02
76.64
94.67
100
62.54
126
101
125
117
69.35
63.79
42.06
34.81
Net Income From Continuing Operations
7.07
7.92
8.47
8.83
9.04
8.81
9.98
13.48
16.11
16.84
23.01
22.51
22.19
21.41
20.40
22.23
27.39
Depreciation, Depletion and Amortization
-1.12
-4.98
-3.21
1.37
-11.78
1.10
-23.07
-1.03
6.05
-23.10
12.99
-16.78
-14.70
15.80
2.35
-2.12
-5.24
  Change In Inventory
1.69
-5.22
4.02
-6.34
-8.47
-3.79
-2.05
-9.75
5.01
-1.63
7.19
-5.19
-2.33
-3.30
0.11
-2.87
1.99
  Change In Prepaid Assets
-1.14
-1.98
1.50
-0.99
9.87
13.38
14.51
-1.34
3.04
-1.72
1.84
6.08
-4.57
-2.66
-0.43
-1.27
2.42
  Change In Payables And Accrued Expense
-14.87
13.48
-0.38
12.58
20.25
15.07
20.94
22.53
-6.52
18.70
-30.80
16.46
-11.46
-9.07
-30.03
-6.75
-10.18
  Change In Other Working Capital
-15.45
1.30
1.94
6.62
9.87
25.76
10.33
10.41
7.59
-7.75
-8.79
0.56
-33.06
0.77
-28.00
-13.00
-11.01
Change In Working Capital
-2.30
3.19
-1.60
4.11
0.81
-1.04
-2.57
-3.70
19.31
0.70
-3.64
-2.42
-2.97
-7.18
-2.75
-6.74
-7.94
Deferred Tax
8.93
10.41
10.55
10.21
7.62
9.81
11.08
16.54
15.48
14.96
15.54
14.39
14.30
13.33
14.60
14.56
13.77
Stock Based Compensation
--
--
--
--
--
--
--
--
2.73
-0.66
--
0.51
4.20
6.08
2.60
1.89
2.17
Asset Impairment Charge
0.66
-2.36
-0.00
-3.40
-7.48
-14.79
-12.02
0.12
0.02
1.81
0.08
0.19
0.06
0.14
0.01
0.00
-0.40
Cash Flow from Others
32.47
66.11
70.11
92.81
98.89
105
111
137
124
152
127
160
121
104
70.64
60.99
58.79
Cash Flow from Operations
-4.13
-4.19
-10.64
-8.43
-8.05
-20.42
-23.73
-32.70
-13.22
-11.43
-16.57
-15.09
-12.76
-10.40
-14.49
-10.07
-9.68
Purchase Of Property, Plant, Equipment
0.84
0.03
0.03
0.15
0.05
0.01
0.19
0.01
0.02
0.38
0.02
0.01
0.02
0.01
0.02
0.06
0.06
Sale Of Property, Plant, Equipment
--
-42.69
--
--
--
--
--
--
--
--
--
--
--
-6.53
--
-203
-- Purchase Of Business
--
--
--
--
-8.64
-3.87
--
--
--
-86.40
-1.66
-21.09
-1.56
--
-1.27
-0.87
-1.07
Purchase Of Investment
--
--
--
--
--
12.51
--
--
--
23.60
65.48
1.94
--
4.56
3.78
1.13
-- Sale Of Investment
0.09
--
0.00
-0.00
-4.94
-4.50
-1.58
0.80
0.30
4.85
0.23
0.28
0.12
0.00
--
0.00
-202
Cash From Other Investing Activities
-3.20
-46.85
-10.61
-8.28
-21.59
-16.27
-25.12
-31.88
-12.90
-69.00
47.49
-33.96
-14.19
-12.37
-11.98
-213
-213
Cash Flow from Investing
-1.65
-17.03
-33.46
-68.29
-18.09
-139
-61.18
-64.61
-50.00
-105
-150
-57.03
-178
-25.38
-11.60
-9.44
-12.30
Repurchase of Stock
57.02
69.30
--
1.85
--
30.00
--
73.70
3.50
--
5.00
60.00
--
11.00
1.54
23.69
23.15
  Issuance of Debt
-85.01
-76.30
--
-1.85
--
-30.00
--
-73.70
-3.50
--
-5.00
-60.00
--
-11.00
-0.75
-1.47
-1.47
  Payments of Debt
-27.99
-7.00
--
--
--
--
--
--
--
--
--
--
--
--
0.79
22.22
21.68
Net Issuance of Debt
0.14
14.45
0.09
3.75
7.92
25.80
12.02
-0.25
-0.32
0.10
-2.05
-2.41
-3.58
-4.71
-3.43
-3.22
-2.35
Other Financing
-29.50
-9.58
-33.37
-64.54
-10.17
-113
-49.16
-64.86
-50.32
-105
-152
-59.44
-181
-30.09
-14.24
9.55
7.03
Cash Flow from Financing
13.28
13.66
24.22
50.35
70.84
137
111
147
179
251
217
238
316
244
291
333
331
Beginning Cash Position
0.61
0.89
0.00
0.50
-0.64
-2.12
-5.10
-7.93
11.03
-11.14
-1.72
11.25
2.09
-13.78
-2.50
-6.19
-1.67
  Effect of Exchange Rate Changes
0.38
10.56
26.13
20.49
66.50
-26.22
32.08
32.22
71.58
-33.30
20.45
78.25
-72.28
47.67
41.93
-149
-149
Net Change in Cash
13.66
24.22
50.35
70.84
137
111
143
179
251
217
238
316
244
291
333
185
182
Ending Cash Position
-4.13
-4.19
-10.64
-8.43
-8.05
-20.42
-23.73
-32.70
-13.22
-11.43
-16.57
-15.09
-12.76
-10.40
-14.49
-10.07
-9.68
Capital Expenditure
28.34
61.92
59.47
84.37
90.84
84.76
87.74
104
111
141
110
145
108
93.50
56.15
50.92
49.12
Free Cash Flow
* All financial numbers are in millions except for per share data, ratios and percentage change.
GuruFocus Manual of Stocks™  |  Jul 07, 2025
Usana Health Sciences Inc (NYSE:USNA)
www.gurufocus.com/stock/NYSE:USNA/summary

Financial Satement

Balance Sheet

Dec09
Dec10
Dec11
Dec12
Dec13
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Dec22
Dec23
Dec24
TTM Fiscal Period
13.66
24.22
50.35
70.84
137
111
143
176
247
214
235
312
240
288
330
182
180
  Cash And Cash Equivalents
--
--
--
--
8.64
--
--
--
--
63.54
--
--
--
--
--
--
--   Marketable Securities
13.66
24.22
50.35
70.84
146
111
143
176
247
278
235
312
240
288
330
182
180
Cash, Cash Equivalents, Marketable Securities
2.78
3.74
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--   Accounts Receivable
0.51
3.11
5.66
8.24
13.60
11.03
11.78
17.04
13.46
14.03
8.76
7.42
7.16
7.21
7.20
8.22
--   Other Current Receivables
3.28
6.84
5.66
8.24
13.60
11.03
11.78
17.04
13.46
14.03
8.76
7.42
7.16
7.21
7.20
8.22
-- Total Receivables
6.79
9.37
9.67
9.23
13.82
15.13
22.53
26.19
20.74
19.50
15.88
28.33
30.28
21.78
19.85
24.46
26.79
  Inventories, Raw Materials & Components
5.00
5.79
6.92
7.70
8.15
7.55
8.70
9.46
8.46
14.49
12.11
9.96
9.59
4.29
4.71
3.61
3.80
  Inventories, Work In Process
13.97
18.92
20.38
19.55
25.27
22.58
34.89
29.17
33.72
47.96
40.92
51.94
58.45
41.03
36.90
41.66
42.97
  Inventories, Finished Goods
-0.00
--
--
--
-0.00
-0.00
--
--
--
--
--
0.00
--
--
--
--
--   Inventories, Other
25.76
34.08
36.97
36.48
47.24
45.25
66.12
64.81
62.92
81.95
68.91
90.22
98.32
67.09
61.45
69.74
73.56
Total Inventories
9.23
15.13
13.08
16.99
22.22
23.53
23.15
20.23
16.65
18.49
16.78
15.73
19.80
21.66
18.67
19.46
28.22
Other Current Assets
51.93
80.27
106
133
229
191
244
278
340
392
329
425
365
384
418
279
281
Total Current Assets
9.38
10.16
10.16
10.41
9.40
8.91
8.41
8.91
10.59
10.13
9.92
10.47
10.37
9.99
9.98
9.58
--   Land And Improvements
37.95
39.33
40.17
40.77
39.50
38.92
38.24
70.72
73.34
71.33
71.26
79.67
80.82
78.07
77.80
76.68
--   Buildings And Improvements
48.48
50.75
36.03
38.27
38.64
36.52
40.10
48.33
57.14
58.62
60.51
63.19
63.92
63.31
62.32
67.18
--   Machinery, Furniture, Equipment
0.68
0.22
1.42
1.57
2.69
14.86
33.04
7.10
4.17
2.45
11.49
11.07
5.50
6.08
9.81
4.62
--   Construction In Progress
4.48
5.40
27.41
29.78
31.68
36.32
39.22
42.00
43.80
45.07
46.58
52.44
62.76
65.07
68.84
66.59
94.25
  Other Gross PPE
101
106
115
121
122
136
159
177
189
188
200
217
223
223
229
225
94.25
Gross Property, Plant and Equipment
-43.71
-48.30
-54.44
-59.05
-62.72
-64.37
-71.03
-75.79
-86.20
-95.56
-105
-116
-122
-125
-129
-130
--   Accumulated Depreciation
57.24
57.57
60.75
61.75
59.18
71.16
87.98
101
103
92.03
95.23
100
102
97.77
99.81
94.57
94.25
Property, Plant and Equipment
5.69
57.55
60.38
59.98
60.57
58.89
55.70
51.06
52.57
48.63
46.48
48.16
48.11
49.80
47.02
296
291
Intangible Assets
5.69
16.93
17.74
17.89
18.24
17.94
17.43
16.72
17.42
16.82
16.64
17.37
17.67
17.37
17.10
144
144
  Goodwill
8.58
8.42
17.31
13.08
19.67
29.60
35.29
40.45
23.69
21.48
45.95
66.99
62.73
64.59
68.18
78.45
79.58
Other Long Term Assets
71.51
124
138
135
139
160
179
193
179
162
188
216
213
212
215
469
465
Total Long-Term Assets
123
204
244
267
368
351
423
471
519
554
517
641
578
597
633
748
747
Total Assets
5.81
6.45
7.95
7.04
9.50
7.78
10.04
9.04
11.79
9.95
12.53
18.20
13.51
11.05
10.07
11.98
13.97
  Accounts Payable
3.97
6.24
8.40
5.98
11.36
13.75
15.67
17.45
23.68
20.77
16.53
20.27
16.52
16.21
12.53
11.76
--   Total Tax Payable
--
-0.00
--
--
-0.00
--
--
--
--
--
0.00
--
--
--
--
-0.00
--   Other Current Payables
8.51
14.40
--
--
--
1.81
6.86
2.22
--
--
--
--
--
--
9.75
13.57
--   Current Accrued Expense
18.29
27.08
16.36
13.02
20.87
23.34
32.58
28.71
35.47
30.72
29.06
38.46
30.03
27.26
32.35
37.31
13.97
Accounts Payable & Accrued Expense
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.79
23.00
23.00
  Short-Term Debt
--
--
--
--
--
--
--
--
--
--
8.32
8.62
7.08
6.89
7.28
6.01
--   Short-Term Capital Lease Obligation
--
--
--
--
--
--
--
--
--
--
8.32
8.62
7.08
6.89
8.06
29.01
23.00
Short-Term Debt & Capital Lease Obligation
7.39
11.77
10.07
15.60
16.06
15.72
17.64
21.46
17.00
15.06
13.85
15.95
19.64
20.88
13.91
12.05
--   Current Deferred Revenue
--
--
0.97
1.38
5.07
5.27
4.43
--
--
--
--
--
--
--
--
--
--   Current Deferred Taxes Liabilities
7.39
11.77
11.04
16.98
21.13
20.99
22.07
21.46
17.00
15.06
13.85
15.95
19.64
20.88
13.91
12.05
-- DeferredTaxAndRevenue
14.81
18.77
32.30
40.84
53.88
64.38
76.77
88.32
88.72
103
84.86
105
104
88.81
64.52
61.25
100
Other Current Liabilities
40.48
57.62
59.70
70.84
95.87
109
131
138
141
149
136
168
161
144
119
140
137
Total Current Liabilities
7.00
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--   Long-Term Debt
7.00
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
-- Long-Term Debt & Capital Lease Obligation
0.09
--
--
--
--
--
--
--
--
--
0.02
0.02
0.02
0.02
0.02
0.06
0.04
Debt-to-Equity
--
--
9.95
10.00
10.87
10.60
9.82
5.50
13.73
13.37
10.28
12.01
7.50
4.07
4.55
4.07
4.80
NonCurrent Deferred Liabilities
1.59
1.01
0.94
0.94
1.21
1.11
1.15
1.36
1.15
1.26
18.84
19.16
14.33
14.17
12.16
18.16
20.54
Other Long-Term Liabilities
8.59
1.01
10.89
10.94
12.08
11.72
10.97
6.86
14.88
14.63
29.12
31.16
21.83
18.24
16.71
22.24
25.34
Total Long-Term Liabilities
49.07
58.64
70.59
81.78
108
120
142
145
156
163
165
199
183
162
136
162
163
Total Liabilities
0.02
0.02
0.02
0.01
0.01
0.01
0.03
0.02
0.02
0.02
0.02
0.02
0.02
0.02
0.02
0.02
0.02
Common Stock
56.41
90.21
119
135
200
166
215
265
288
330
306
383
345
392
445
479
478
Retained Earnings
1.52
3.72
5.84
6.94
5.79
2.13
-3.78
-11.65
-1.43
-10.39
-13.90
-3.63
0.46
-12.79
-13.70
-22.67
-22.75
Accumulated other comprehensive income (loss)
16.43
51.22
49.26
43.82
54.69
61.61
69.73
71.51
76.54
72.01
59.45
62.46
50.01
55.60
65.66
75.82
74.87
Additional Paid-In Capital
0.00
--
--
-0.00
--
-0.00
--
--
--
0.00
--
--
--
-0.00
--
--
-0.00
Other Stockholders Equity
74.37
145
174
186
261
230
281
325
363
391
352
442
395
434
497
532
530
Total Stockholders Equity
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
54.22
54.11
Minority Interest
74.37
145
174
186
261
230
281
325
363
391
352
442
395
434
497
586
584
Total Equity
0.60
0.71
0.71
0.69
0.71
0.66
0.66
0.69
0.70
0.71
0.68
0.69
0.68
0.73
0.79
0.71
0.71
Equity-to-Asset
* All financial numbers are in millions except for per share data, ratios and percentage change.
GuruFocus Manual of Stocks™  |  Jul 07, 2025
Usana Health Sciences Inc (NYSE:USNA)
www.gurufocus.com/stock/NYSE:USNA/summary

Valuation Ratios

Valuation Ratios

Dec09
Dec10
Dec11
Dec12
Dec13
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Dec22
Dec23
Dec24
TTM Fiscal Period
14.70
15.20
9.32
7.40
13.59
18.32
17.79
15.34
29.27
22.99
17.81
13.16
17.66
14.82
16.24
16.39
18.01
PE Ratio
14.91
15.20
9.32
7.40
13.59
18.32
17.79
15.34
18.24
22.82
17.81
13.16
17.66
14.82
16.24
13.86
13.27
PE Ratio without NRI
41.86
15.21
9.48
6.06
11.67
12.91
16.63
14.72
20.28
24.35
18.26
12.61
22.05
14.19
25.33
20.59
19.01
Price-to-Owner-Earnings
6.57
4.58
2.61
2.45
4.03
5.63
5.68
4.61
4.90
7.09
4.84
3.67
4.97
2.35
2.06
1.29
1.16
PB Ratio
7.11
7.59
4.00
3.62
5.25
7.57
7.09
5.46
5.73
8.10
5.57
4.12
5.66
2.66
2.28
2.90
2.58
Price-to-Tangible-Book
17.37
11.19
7.96
5.83
11.82
16.57
19.19
14.71
16.55
20.62
16.27
11.28
18.98
10.99
18.47
13.51
12.74
Price-to-Free-Cash-Flow
15.16
10.48
6.75
5.30
10.86
13.35
15.11
11.20
14.78
19.07
14.14
10.22
16.98
9.89
14.68
11.28
10.64
Price-to-Operating-Cash-Flow
1.13
1.34
0.81
0.76
1.49
1.78
1.83
1.52
1.75
2.44
1.69
1.44
1.74
1.03
1.13
0.80
0.71
PS Ratio
--
5.47
1.56
0.55
0.56
0.90
0.93
0.90
1.61
1.79
1.70
1.32
1.48
3.63
--
--
-- PEG Ratio
1.10
1.24
0.69
0.59
1.26
1.50
1.58
1.31
1.46
2.10
1.39
1.16
1.46
0.74
0.76
0.69
0.58
EV-to-Revenue
8.21
8.34
4.69
3.58
7.19
9.51
9.52
8.67
10.16
11.98
8.50
6.56
8.97
5.68
5.71
5.92
5.40
EV-to-EBITDA
9.34
9.30
5.21
3.90
7.75
10.23
10.18
9.52
11.37
13.03
9.79
7.39
10.13
6.80
6.84
7.64
7.62
EV-to-EBIT
17.00
10.35
6.79
4.56
9.95
13.98
16.55
12.69
13.86
17.75
13.38
9.08
15.95
7.92
12.52
11.50
10.34
EV-to-FCF
10.71
10.75
19.19
25.64
12.90
9.78
9.82
10.50
8.80
7.67
10.21
13.53
9.87
14.71
14.62
13.09
13.12
Earnings Yield (Joel Greenblatt) %
6.32
8.36
14.58
23.43
25.54
24.97
23.56
22.34
16.29
16.33
16.23
16.70
17.46
14.75
4.68
2.94
1.30
Forward Rate of Return (Yacktman) %
21.31
24.32
14.12
12.76
24.75
29.76
32.36
26.80
30.48
40.89
24.10
20.72
23.17
11.26
11.05
7.42
6.76
Shiller PE Ratio
13.86
14.47
7.50
6.20
11.10
12.24
12.41
9.75
9.51
12.41
7.08
6.13
6.79
3.10
2.80
1.69
1.50
Cyclically Adjusted PB Ratio
1.90
2.23
1.32
1.22
2.42
2.88
3.12
2.58
2.74
3.82
2.28
2.01
2.26
1.06
1.01
0.65
0.58
Cyclically Adjusted PS Ratio
21.06
22.50
12.93
11.45
22.40
26.72
29.96
25.13
26.16
35.19
20.61
17.85
20.51
9.90
9.88
6.62
5.99
Cyclically Adjusted Price-to-FCF
5.80
9.31
13.10
18.53
8.66
6.54
5.50
6.95
6.21
5.07
6.48
8.96
5.53
9.15
5.48
7.44
8.05
FCF Yield %

Valuation and Quality

Dec09
Dec10
Dec11
Dec12
Dec13
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Dec22
Dec23
Dec24
TTM Fiscal Period
488
665
454
455
1,050
1,296
1,595
1,498
1,779
2,775
1,701
1,622
1,963
1,022
1,025
684
610
Market Cap
482
641
404
384
904
1,185
1,452
1,323
1,532
2,497
1,474
1,319
1,730
740
703
586
508
Enterprise Value
15.95
21.73
15.19
16.47
37.79
51.30
63.88
61.20
74.05
118
78.55
77.10
101
53.20
53.60
35.89
32.77
Month End Stock Price
-1.16
-1.12
-0.68
-0.40
1.37
-0.37
0.03
1.24
3.79
4.86
3.21
5.36
2.95
6.58
10.19
-1.80
-1.98
Net Cash per Share
0.09
0.71
1.19
1.84
4.36
2.79
4.08
5.41
7.66
9.72
7.58
10.74
9.41
11.57
14.75
3.31
3.44
Net Current Asset Value
-0.67
-0.48
-0.06
0.26
2.22
0.53
1.36
2.57
5.10
6.60
4.81
7.50
5.49
8.32
11.79
0.03
-0.02
Net-Net Working Capital
18.98
20.39
25.26
30.18
36.96
45.67
52.19
60.80
68.65
75.65
82.82
86.17
91.31
82.16
76.47
70.31
68.27
Intrinsic Value: Projected FCF
21.02
24.16
27.91
32.56
35.71
40.14
48.17
55.52
58.50
69.83
71.47
84.22
95.21
84.48
76.65
70.84
72.25
Median PS Value
--
--
9.72
29.86
67.09
57.06
68.40
67.79
44.37
65.25
46.19
58.31
68.23
--
--
--
-- Peter Lynch Fair Value
7.35
9.60
11.81
15.08
21.22
20.67
26.98
31.71
34.37
41.08
37.40
49.66
48.03
40.22
41.80
26.87
26.56
Graham Number
25.32
23.87
26.46
29.83
35.38
39.65
44.04
51.93
57.89
63.50
72.82
83.39
90.37
95.61
88.66
71.71
70.76
Earnings Power Value (EPV)
11.64
11.22
8.19
7.96
10.02
10.75
11.04
10.44
10.95
14.84
10.47
8.89
10.74
7.46
8.08
5.14
4.85
Altman Z-Score
6.00
8.00
7.00
7.00
9.00
5.00
8.00
6.00
7.00
8.00
5.00
8.00
6.00
6.00
7.00
6.00
5.00
Piotroski F-Score
-2.76
-1.20
-2.96
-2.64
-2.26
-2.98
-2.64
-2.49
-3.33
-2.70
-2.95
-2.84
-2.53
-2.66
-2.48
-1.77
-1.97
Beneish M-Score
0.55
0.98
0.61
0.47
0.43
0.32
0.39
0.35
0.25
0.22
0.23
0.27
0.25
0.27
0.29
0.69
0.57
Scaled Net Operating Assets
3.47
12.95
-3.58
-6.77
0.47
-3.50
1.97
-1.06
-9.31
7.77
-14.26
-0.28
1.64
-3.72
0.81
25.95
25.30
Sloan Ratio %
1.28
1.39
1.78
1.87
2.39
1.76
1.86
2.01
2.41
2.64
2.42
2.53
2.27
2.67
3.52
2.00
2.05
Current Ratio
0.65
0.80
1.16
1.36
1.90
1.34
1.36
1.54
1.96
2.09
1.91
1.99
1.66
2.21
3.00
1.50
1.51
Quick Ratio
0.34
0.42
0.84
1.00
1.52
1.02
1.09
1.27
1.75
1.87
1.73
1.86
1.49
2.01
2.78
1.30
1.31
Cash Ratio
83.40
726
8,584
4,909
116,712
900
9,444
312
2,881
5,232
2,215
348
2,986
560
355
236
89.57
Interest Coverage
18.50
22.54
21.73
24.63
45.71
59.09
88.06
74.13
75.60
136
119
91.20
106
103
67.92
54.45
48.85
Highest Stock Price
9.30
12.32
11.80
15.46
16.44
28.81
48.97
47.41
54.25
70.75
58.92
45.78
77.95
48.66
44.44
33.38
23.10
Lowest Stock Price
0.27
--
2.41
7.49
-0.47
9.02
1.15
1.97
1.88
1.90
8.11
2.85
7.82
0.96
0.40
0.35
1.37
Shares Buyback Ratio %
0.34
2.56
7.37
15.00
1.72
10.71
3.83
4.31
2.81
3.80
8.82
3.52
9.06
2.48
1.13
1.38
2.02
Buyback Yield %
6.68
14.68
15.08
16.34
16.31
14.21
20.70
15.26
5.52
13.86
-3.66
14.81
9.26
-11.33
-7.94
-6.33
-1.51
YoY Rev. per Sh. Growth
17.30
31.80
13.99
36.50
24.94
0.72
28.21
11.14
-36.59
102
-13.87
32.88
-2.22
-37.35
-8.08
-33.64
-43.30
YoY EPS Growth
14.11
26.89
14.48
30.22
23.04
2.92
27.20
5.16
0.25
38.57
-10.05
24.28
0.30
-28.88
-5.63
-18.93
-21.77
YoY EBITDA Growth
-0.03
2.78
5.97
13.39
24.09
20.27
19.08
16.99
11.32
12.77
10.45
9.95
11.95
4.08
-4.72
-10.28
-9.40
5-Year EBITDA Growth Rate
30.68
31.06
30.72
29.09
27.39
26.44
25.46
24.19
24.35
24.11
22.64
21.16
20.15
19.25
19.25
19.10
19.05
Shares Outstanding (Basic Average)
30.62
30.62
29.88
27.64
27.77
25.27
24.98
24.49
24.02
23.57
21.66
21.04
19.39
19.21
19.13
19.06
18.62
Shares Outstanding (EOP)
0.79
0.85
1.25
0.88
1.27
2.22
1.00
1.08
0.02
0.64
0.48
0.96
1.07
0.77
0.57
0.70
0.99
Beta
03/17/10
03/14/11
03/14/12
03/11/13
03/13/14
03/17/15
03/01/16
03/01/17
02/28/18
02/26/19
02/25/20
03/02/21
03/01/22
02/28/23
02/27/24
03/12/25
  Filing Date
03/14/11
03/11/13
03/13/14
03/17/15
03/01/16
03/01/17
02/28/18
02/26/19
02/25/20
03/02/21
03/01/22
02/28/23
02/27/24
03/12/25
03/12/25
03/12/25
  Restated Filing Date
02/09/10
02/08/12
02/06/13
02/05/14
02/11/15
02/10/16
02/08/17
02/06/18
02/05/19
02/05/20
02/09/21
02/09/22
02/08/23
02/07/24
02/26/25
  Earnings Release Date
414
410
384
370
330
317
294
288
277
261
260
254
247
244
237
230
230
Number of Shareholders
930
1,240
1,290
1,330
1,480
1,527
1,664
1,788
1,810
1,911
1,909
1,943
1,978
1,900
1,900
1,700
1,700
Number of Employees
* All financial numbers are in millions except for per share data, ratios and percentage change.
GuruFocus Manual of Stocks™  |  Jul 07, 2025
Usana Health Sciences Inc (NYSE:USNA)
www.gurufocus.com/stock/NYSE:USNA/summary

Business & Geographic Segmentation

Business Segments

Dec09
Dec10
Dec11
Dec12
Dec13
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Dec22
Dec23
Dec24
TTM Fiscal Period
--
--
--
--
--
--
--
--
--
--
--
--
1,186
995
915
846
830
Direct selling
--
--
--
--
--
--
--
10.06
20.95
11.89
10.61
11.35
--
3.56
5.80
6.74
7.09
Other
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
1.97
39.06
Hiya direct-to-consumer
--
--
--
--
--
--
--
835
869
975
881
964
1,020
--
--
--
-- USANA Nutritionals
--
--
--
--
--
--
--
101
94.25
107
84.87
79.43
83.05
--
--
--
-- USANA Foods
--
--
--
--
--
--
--
--
--
--
84.87
79.43
71.19
--
--
--
-- Personal care and Skincare
--
--
--
--
--
--
--
--
--
59.46
--
--
--
--
--
--
-- Celavive
--
--
--
--
--
--
--
60.37
62.84
35.68
--
--
--
--
--
--
-- Sense-beautiful science

Geographic Segments

Dec09
Dec10
Dec11
Dec12
Dec13
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Dec22
Dec23
Dec24
TTM Fiscal Period
--
--
--
--
--
--
--
217
483
587
471
470
506
453
427
413
-- China
--
--
--
--
--
--
--
206
205
225
220
270
270
190
164
147
-- Southeast Asia Pacific
--
--
--
--
--
--
--
140
121
116
105
--
--
106
95.91
91.80
-- United States
--
--
--
--
--
--
--
111
116
116
104
220
223
90.60
84.67
79.72
-- Americas and Europe
--
--
--
--
--
--
--
--
--
--
--
--
--
--
99.11
76.45
-- South Korea
--
--
--
--
--
--
--
285
63.81
67.88
64.83
60.33
57.37
49.35
47.83
44.51
-- Greater China
--
--
--
--
--
--
--
46.02
58.38
76.72
96.19
115
130
109
2.34
1.77
-- North Asia
* All financial numbers are in millions except for per share data, ratios and percentage change.
GuruFocus Manual of Stocks™  |  Jul 07, 2025
Usana Health Sciences Inc (NYSE:USNA)
www.gurufocus.com/stock/NYSE:USNA/summary

Explanation

1. Predictability Rank

GuruFocus Predictability Rank is a proprietary ranking of the consistency of a business. We rank the predictability of companies based on the consistency of their revenue per share and EBITDA (earnings before interest, tax, depreciation and amortization) per share over the past 10 fiscal years. Our study found that there is a strong correlation between the stock performance and the predictability of a business. Over the long term, companies with higher predictability also have better stock performance.

The rank is from 1-star to 5-star, with 5-star as the best.

2. Financial Strength

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:

  1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
  2. Debt to revenue ratio. The lower, the better.
  3. Altman Z-Score.

The rank is from 1 to 10, with 10 as the highest.

A Financial Strength rank of 8 or above indicates good financial strength; between 4-7 indicates fair financial strength; 3 or below means poor financial strength.

3. Profitability Rank

GuruFocus Profitability Rank indicates how profitable a company is and how likely it is that the company's business will stay that way. It is based on these factors:

  1. Operating Margin %.
  2. Piotroski F-Score.
  3. Trend of the Operating Margin percentage (five-year average). A company with an uptrend in profit margin will have a higher rank.
  4. Consistency of the profitability.
  5. Predictability Rank.

The rank is from 1 to 10, with 10 as the highest.

A Profitability Rank of 8 or above indicates good profitability; between 4-7 indicates fair profitability; 3 or below means poor profitability.

4. Peter Lynch Chart

In Peter Lynch's excellent book, "One Up on Wall Street," he used many charts to illustrate the valuation of stocks. “A quick way to tell if a stock is overpriced is to compare the price line to the earnings line. If you bought familiar growth companies – such as Shoney’s, The Limited, or Marriott – when the stock price fell well below the earnings line, and sold them when the stock price rose dramatically above it, the chances are you’d do pretty well.”

The original Peter Lynch Chart does have limitations due to the right side price scale is pre-set at 15 times the earnings scale on the left side. When the stock price and earnings line coincide, the price-to-earnings ratio is always 15 times. Instead of using the fixed PE Ratio of 15, our approach is using 15-year historical median PE without NRI Ratio for each stock.

The Peter Lynch Chart with earnings line at median PE without NRI ratio works well for the companies with steady growth and earnings trends, or the stalwarts, as coined by Lynch. These companies tend to be found in sectors such as consumer staples, healthcare, and utilities, where the consumption of the product or service is relatively independent of economic conditions. It does not work well with the sectors that are cyclical: industrials, chemicals, durable goods, and so forth.

5. GF Value

Based on the relationship between the current stock price and the GF Value, GuruFocus provides the following 6 evaluations:

  1. Possible Value Trap, Think Twice
  2. Significantly Overvalued
  3. Modestly Overvalued
  4. Fairly Valued
  5. Modestly Undervalued
  6. Significantly Undervalued
There is only a sufficient margin of safety when the stock is undervalued.

Disclaimer

GuruFocus.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The gurus may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.